1. Home
  2. PWR vs REGN Comparison

PWR vs REGN Comparison

Compare PWR & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanta Services Inc.

PWR

Quanta Services Inc.

N/A

Current Price

$421.99

Market Cap

66.0B

Sector

Industrials

ML Signal

N/A

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

N/A

Current Price

$747.29

Market Cap

73.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PWR
REGN
Founded
1997
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
66.0B
73.9B
IPO Year
1998
1991

Fundamental Metrics

Financial Performance
Metric
PWR
REGN
Price
$421.99
$747.29
Analyst Decision
Buy
Buy
Analyst Count
21
23
Target Price
$422.95
$795.74
AVG Volume (30 Days)
1.0M
1.1M
Earning Date
10-30-2025
02-03-2026
Dividend Yield
0.10%
0.47%
EPS Growth
24.72
2.88
EPS
6.75
41.59
Revenue
$27,191,171,000.00
$14,247,800,000.00
Revenue This Year
$19.56
$1.95
Revenue Next Year
$12.24
$5.47
P/E Ratio
$62.45
$18.00
Revenue Growth
18.72
2.89
52 Week Low
$227.08
$476.49
52 Week High
$473.99
$790.98

Technical Indicators

Market Signals
Indicator
PWR
REGN
Relative Strength Index (RSI) 41.83 62.66
Support Level $411.41 $739.23
Resistance Level $441.41 $757.35
Average True Range (ATR) 14.85 18.64
MACD -5.05 -1.75
Stochastic Oscillator 21.14 98.51

Price Performance

Historical Comparison
PWR
REGN

About PWR Quanta Services Inc.

Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two segments: electric infrastructure and underground utility and infrastructure.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Share on Social Networks: